- Visibility19
- Citations1
- Sentiment93
- Site quality87
- AI readiness21
AI assistants name Vertex Pharmaceuticals in 11.7% of answers, which is more frequent than the typical company in its sector at 3.3%. Its overall score is 41 out of 100, ranking 341st of 2,047 companies and seventh of 105 in its sector. The Vertex Pharmaceuticals website passes 3 of 14 technical checks for AI tool readiness.
We asked 15 unbranded questions about the healthcare market: none named Vertex Pharmaceuticals. AI assistants named it in 7 of 60 answers (11.7%). The typical healthcare company is named in 3.3% of answers. By how often it is named, Vertex Pharmaceuticals ranks 20 of 105 in its sector.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“What are the best biopharmaceutical companies focusing on rare diseases in the United States?”
Many biopharmaceutical companies in the United States are dedicated to developing treatments for rare diseases. These companies often focus on precision genetic medicine, gene therapy, and biologics.
Some of the leading biopharmaceutical companies focusing on rare diseases in the United States include:
Sarepta Therapeutics: Specializes in precision genetic medicine for neuromuscular rare diseases.
Ultragenyx Pharmaceutical: Focuses on gene therapy and biologics for rare and ultra-rare genetic diseases.
Intellia Therapeutics: Known for its work in in vivo CRISPR/Cas9 g …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
The website turns away requests that do not come from a browser. AI agents that say what they are meet the same refusal.
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 25 of 100 · 97% of checks could run · checked on October 3, 2026 · vrtx.com · 2,047 companies scanned
3 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- Not metHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotpartly
- ClaudeBotpartly
- Anthropic-AIpartly
- Google-Extendedpartly
- Applebot-Extendedpartly
- Meta-ExternalAgentpartly
- FacebookBotpartly
- Bytespiderpartly
- CCBotpartly
- Diffbotpartly
- Omgilibotpartly
- OAI-SearchBotpartly
- Claude-SearchBotpartly
- PerplexityBotpartly
- Applebotpartly
- Amazonbotpartly
- YouBotpartly
- ChatGPT-Userpartly
- Claude-Userpartly
- Perplexity-Userpartly
- DuckAssistBotpartly
- MistralAI-Userpartly
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as S&P 500.
- What are the best biopharmaceutical companies focusing on rare diseases in the United States?
- What should patients do if they experience unexpected side effects from biopharmaceutical treatments?
- Is investing in biopharmaceutical stocks focused on rare disease treatment worth it?
- Why are treatments from biopharmaceutical companies often more expensive than standard medicines?
- How are prices determined for advanced therapies developed by American biopharmaceutical companies?
- How can healthcare professionals report issues with recently approved biopharmaceutical medicines?
- Are there non-pharmaceutical approaches to treating conditions typically targeted by biopharmaceutical innovation?
- How are biopharmaceutical therapies transforming the treatment of chronic genetic conditions?
- How do biopharmaceutical companies compare to traditional pharmaceutical companies in terms of innovation?
- Are new therapies from biopharmaceutical companies for serious diseases effective?
- What alternatives exist to biopharmaceutical therapies for managing rare genetic diseases?
- What emerging fields are providing alternatives to traditional biopharmaceutical development for serious diseases?
- Who can benefit most from innovative medicines developed by biopharmaceutical companies?
- Biopharmaceutical companies vs medical device companies: Which contribute more to treatment advancements?
- Which companies lead in developing transformative medicines for cystic fibrosis?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.
A badge of this result that you can show on your own website. Copy the code below.
<a href="https://aeo-audit.rezolve.com/us/vrtx.com"><img src="https://aeo-audit.rezolve.com/us/badges/vrtx.com.svg" alt="Overall score 41 of 100, US AI Visibility Study 2026" width="280" height="64"></a>